Compare ENR & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | TYRA |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2015 | 2021 |
| Metric | ENR | TYRA |
|---|---|---|
| Price | $20.46 | $32.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $25.00 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 1.3M | 740.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.56% | N/A |
| EPS Growth | ★ 538.46 | 6.79 |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | N/A |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | $6.48 | ★ N/A |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $16.77 | $6.42 |
| 52 Week High | $31.78 | $35.71 |
| Indicator | ENR | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 57.45 |
| Support Level | $19.45 | $26.14 |
| Resistance Level | $20.92 | N/A |
| Average True Range (ATR) | 0.84 | 2.63 |
| MACD | -0.30 | 0.13 |
| Stochastic Oscillator | 2.05 | 71.05 |
Energizer Holdings Inc. manufactures and distributes household batteries, specialty batteries, and lighting products. The company offers batteries using lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide technologies, sold under the Energizer, Rayovac, Varta, and Eveready brands across performance and premium price segments. It also provides auto care products in the appearance, fragrance, performance, and air conditioning recharge categories. Energizer operates through two geographical segments, the United States and International, with the majority of its revenue generated in the United States. It has two product segments: Batteries and Lights and Auto Care, with the Batteries and Lights segment contributing the majority of its revenue.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.